We are live on ! Find out more
HBIO icon

Harvard Bioscience

81 hedge funds and large institutions have $65.1M invested in Harvard Bioscience in 2016 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 34 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0% more funds holding

Funds holding: 8181 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

10% less capital invested

Capital invested by funds: $72.1M → $65.1M (-$6.99M)

44% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 34

Holders
81
Holders Change
Holders Change %
0%
% of All Funds
2.16%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
15
Increased
19
Reduced
34
Closed
14
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Two Sigma Advisers
51
Two Sigma Advisers
New York
$87K -$2.86K -90 -3%
PAM
52
Panagora Asset Management
Massachusetts
$81K -$203K -6,378 -69%
T. Rowe Price Associates
53
T. Rowe Price Associates
Maryland
$81K -$318 -10 -0.4%
LP
54
LMR Partners
United Kingdom
$78K +$86.5K +2,720 New
BG
55
BlackRock Group
United Kingdom
$76K
EA
56
Emerald Acquisition
Washington
$75K +$83.2K +2,616 New
Asset Management One
57
Asset Management One
Japan
$74K
AGM
58
Alpine Global Management
New York
$71K +$78.8K +2,478 New
Jane Street
59
Jane Street
New York
$57K +$63.6K +2,001 New
Charles Schwab
60
Charles Schwab
California
$56K -$238K -7,493 -80%
DIA
61
Denver Investment Advisors
Colorado
$49K -$11.4K -357 -17%
State Street
62
State Street
Massachusetts
$42K -$961K -30,214 -95%
MFW
63
Meristem Family Wealth
Minnesota
$35K +$39.3K +1,237 New
OAM
64
Oxford Asset Management
United Kingdom
$35K +$39.4K +1,239 New
Squarepoint
65
Squarepoint
New York
$32K +$35.6K +1,120 New
Two Sigma Investments
66
Two Sigma Investments
New York
$31K -$4.45K -140 -11%
MFS
67
MSI Financial Services
Massachusetts
$29K
New York State Common Retirement Fund
68
New York State Common Retirement Fund
New York
$26K -$68.1K -2,140 -70%
NFA
69
Nationwide Fund Advisors
Ohio
$25K -$67.8K -2,131 -71%
TRCT
70
Tower Research Capital (TRC)
New York
$25K +$28.3K +890 New
JC
71
JBF Capital
Colorado
$18K
AIM
72
Acrospire Investment Management
Illinois
$17K +$8.59K +270 +80%
BIM
73
BlackRock Investment Management
Delaware
$16K -$385K -12,094 -95%
Walleye Trading
74
Walleye Trading
New York
$15K -$27.4K -860 -62%
Royal Bank of Canada
75
Royal Bank of Canada
Ontario, Canada
$14K -$12.7K -400 -44%

HBIO Hedge Fund Activity: Q2 2016 in Review

81 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2016, worth a combined $65.1M — down 9.7% from $72.1M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new HBIO positions and 14 closed out — a net gain of 1 holder — while 19 added to existing stakes and 34 trimmed.

The largest buyer was First Light Asset Management, adding an estimated $1.88M. The largest seller was BlackRock Fund Advisors, cutting an estimated $2.52M.

  • 81 institutional investors held Harvard Bioscience (HBIO) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $65.1M of Harvard Bioscience stock for Q2 2016, down 9.7% quarter-over-quarter.
  • 15 funds opened new Harvard Bioscience positions in Q2 2016 and 14 closed out, a net change of +1 holder.
  • The largest Harvard Bioscience buyer in Q2 2016 was First Light Asset Management, an estimated $1.88M added.
  • The largest Harvard Bioscience seller in Q2 2016 was BlackRock Fund Advisors, an estimated $2.52M sold.

Based on aggregated 13F filings for Q2 2016.